Analysts anticipate Castle Biosciences to report an earnings per share (EPS) of $-0.44.
The announcement from Castle Biosciences is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Past Earnings Performance
During the last quarter, the company reported an EPS beat by $0.65, leading to a 32.83% increase in the share price on the subsequent day.
Here's a look at Castle Biosciences's past performance and the resulting price change:
Quarter
Q2 2025
Q1 2025
Q4 2024
Q3 2024
EPS Estimate
-0.50
-0.07
0.04
-0.06
EPS Actual
0.15
-0.20
0.32
0.08
Price Change %
33.00
-11.00
-14.00
-7.00
Stock Performance
Shares of Castle Biosciences were trading at $24.21 as of October 30. Over the last 52-week period, shares are down 25.98%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
Analyst Views on Castle Biosciences
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Castle Biosciences.
Castle Biosciences has received a total of 1 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $37.0, ...
